Analysts cheer signs of turnaround at Merck

Analysts cheered on Merck's encouraging new quarterly report, which is highlighted by a 12 percent increase in revenue, with new and old drugs alike posting strong numbers. For the analysts, the report underscores Merck's progress with a five-year turnaround plan. And it marks the pharma giant's success in combating the effects of new generic competitors. Merck's stock jumped nine percent on the bullish news. Merck's Vioxx defense continued to take a bite out of profits, though. Merck increased its Vioxx reserve to $810 million.

- read the report on Merck from The Washington Post

Related Articles:
Merck touts reorganization effort. Report
Merck faces long road in Vioxx battle. Report
Merck's McGlynn has key role developing vaccines. Report

Suggested Articles

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.